Clinical Trial Update: Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing fluticasone furoate/vilanterol inhalation powder to vilanterol alone in COPD; study completed with posted results in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Fluticasone furoate/vilanterol inhalation powder (fluticasone furoate/vilanterol)
• Vilanterol Inhalation Powder (vilanterol)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 3 | Status: COMPLETED | Results posted: 2016-04-13